Related Experiment Video
Updated: May 16, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Comparative study between the effect of methotrexate and valproic acid on solid Ehrlich tumour.
Mohamed Nabih Abdel-Rahman1, Ahmed Mohammed Kabel
1Department of Pharmacology, Faculty of Medicine, Tanta University, Egypt. drakabel@gmail.com
Journal of the Egyptian National Cancer Institute
|November 20, 2012
Summary
Methotrexate (MTX) and Valproic Acid (VPA) both show anti-cancer effects against solid Ehrlich tumors in mice. MTX demonstrated a more potent anti-tumor effect compared to VPA.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Solid Ehrlich Carcinoma (SEC) is a widely studied undifferentiated tumor.
- Methotrexate (MTX) is an antimetabolite used in cancer therapy.
- Valproic Acid (VPA) is an anticonvulsant with emerging anti-cancer applications.
Purpose of the Study:
- To compare the anti-tumor efficacy of MTX and VPA.
- To evaluate the effects of MTX and VPA on SEC in a murine model.
Main Methods:
- Forty mice with SEC were divided into control, SEC, SEC+MTX, and SEC+VPA groups.
- Assessed tumor volume, tissue antioxidant enzymes (CAT, GR), lipid peroxidation (MDA), cholesterol, and TNF-α.
- Conducted histopathological and immunohistochemical analyses of tumor tissue.
Main Results:
- Both MTX and VPA significantly reduced tumor volume, MDA, cholesterol, and TNF-α.
- MTX and VPA increased tissue CAT and GR levels and p53 expression.
- MTX exhibited a more pronounced anti-tumor effect than VPA.
Conclusions:
- Methotrexate (MTX) possesses a stronger anti-tumor effect against solid Ehrlich Carcinoma (SEC) than Valproic Acid (VPA).
- Both agents modulate key biochemical markers and histopathological features of the tumor.
More Related Videos
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...